02 August 2021 | News
To accelerate the development of the vaccine
image credit- shutterstock
QPS, a global contract research organization (CRO) that focuses on bioanalytical products and clinical trials, has partnered with Taiwan-based Medigen Vaccine Biologics Corporation to complete the toxicology studies necessary to jump-start the development of a vaccine against COVID-19.
Researchers at the Center for Toxicology and Preclinical Sciences (CTPS) in QPS Taiwan have quickly completed studies to accelerate the development of the vaccine, which has just been approved by the Taiwan Food and Drug Administration (TFDA) for the Authorization of Emergency Use (USA) in Taiwan.
Medigen Vaccine Biologics Corporation has also been successful with a one-of-a-kind government grant for the clinical trial of the new vaccine,
CTPS at QPS Taiwan has been the main testing facility to launch the toxicity study of the new vaccine. The researchers accepted the first clinical cases in October 2020 and completed the studies in just a few months. The team met all scientific objectives, analyzing the end points and reporting on all results as scheduled